Journal of Clinical and Surgical Research

Therapeutic interventions are available for patients with primary biliary cholangitis

Martin August — 2022-12-10

The first-line treatment of MM for patients with
primary biliary cholangitis (CEC) currently consists of
ursodeoxycholic acid (UDCA) at 13 to 15 mg/kg per
day, usually divided into two daily doses. It can take up
to 12 months for the UDCA to reach all of its benefits;
however, up to 40% of patients treated with UDCA
will not have an adequate biochemical response after 1
year. In these patients, a farnesoid X receptor agonist
(FXR) (Ocaiva, Intercept) is usually added for secondline
treatment. The double-blind, placebo-controlled,
phase 3, placebo-controlled study showed that UDCAtreated
patients who also received obeticic acid were
about 5 times more likely (46% versus 10% with
placebo) to achieve the goal. Primary compound
(defined as alkaline phosphatase ≤ 1.67 × upper limit
of normal, ≥15% reduction in alkaline phosphatase,
and normalization of bilirubin) than patients treated
with UDCA alone.

Nonalcoholic Fatty Liver Disease in Children

Katherine Christine Lee MD — 2022-09-30

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide.
It is a wide range of diseases from simple cirrhosis to steatohepatitis, which can progress to progressive
liver fibrosis and even cirrhosis. NAFLD is the fastest growing liver transplant for adults. The incidence of
NAFLD in children has also increased over the last decade. Although most children with NAFLD are obese
or obese, there is a growing subgroup of children with a normal body mass index called low NAFLD.
NAFLD in children has been associated with a number of extrahepatic manifestations, including
hyperlipidemia, insulin resistance, and obstructive sleep apnea.The pathogenesis of NAFLD in children
includes multifactorial interactions between genetics, uterine exposure, early childhood exposure, and chronic
nutritional exposure. Although there are some similarities between NAFLD in children and NAFLD in adults,
liver biopsies in children show histological differences between the two.The current treatment for NAFLD in
children is a lifestyle change to reduce calorie intake and increase physical activity. There are currently no
approved drugs for the treatment of NAFLD in children. This article summarizes the current

Centers of excellence in hepatology: a case presentation to insurers, large employers and patients

Lindsay Berg — 2022-09-30

structured, major stakeholders can clearly assess whether a
particular site can represent a center of quality. Patients and
their referral doctors can also access the following
information to help guide informed decision making and
balance matters such as quality and distance and space.
Hospital management uses similar data (including pricing)
to understand where their centers are located in continuing
practice compared to regions and countries. Finally,
insurance companies and employers can use and leverage the
data to identify the Centers of Excellence (CoE) they are
most interested in leading. patients and staff.

Potential Effectiveness of Aloe Vera Gel for Wound Healing and Pain Relief: Case Reports of Campo with Aloe Vera Juice

JuiceAkira Ataka MD, PhD — 2022-09-30

Aloe vera has an anti-inflammatory activity and a stimulant (wound healing action), which can act on behalf of the four ' heal wounds and inflammation. The effect of aloe vera for wound healing, swelling and analgesic was discussed. Aloe vera reduces pain by blocking the secretion of bradykinin, cyclooxygenase-2 and thromboxane synthase. In addition, we present six cases of Kampo with the use of aloe vera juice which proves Kampo as a suitable treatment for wounds and enhances the utilization of natural intestinal microbial organisms in the hospital. Yagi A, Hasegawa M, Ataka S. The efficacy of aloe vera gel in wound healing and pain disorders: report of Kampo and aloe vera juice.

intoxicationUseful use of butyrate, propionate and aloe fermented aloe vera for acute kidney disease and uremic poisoning

Kenji Yagi — 2022-09-30

The gut microbiome plays an important role in maintaining health and in the pathogenesis of disease. The symbiotic relationship between the host and the microbiome is disrupted due to the proliferation of dysbiotic bacteria in patients with chronic kidney disease (CKD). The fermentation of proteins and amino acids by intestinal bacteria leads to the formation of excessive amounts of potentially toxic compounds such as ammonia, amines, thiols, phenols and indoles, but the formation of short-chain fatty acids is reduced.Therefore, reducing the accumulation of uremic toxins by changing the intestinal microbiota is important to prevent kidney damage.